Additionally, some findings indicate that fenofibrate, a clinical treatment of dyslipidemia and insulin resistance, increases vaspin mRNA and protein expression in retroperitoneal adipose tissue (RET), mesenteric adipose tissue (MET), and epididymal adipose tissue (EAT) without the influence of vaspin mRNA in subcutaneous adipose tissue (SAT), which works as a compensatory mechanism in MetS [94]. The gene discussed is SERPINA12; the disease is metabolic syndrome.